FTCM
ASBP

Fir Tree Capital Management’s Aspire Biopharma ASBP Stock Holding History

Fir Tree Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-177
Closed -$2.35M – 103
2024
Q1 		$2.35M Buy
177
+26
+17% +$342K 0.57% 35
2023
Q4 		$1.97M Buy
151
+29
+24% +$382K 0.33% 86
2023
Q3 		$1.71M Buy
122
+66
+118% +$851K 0.18% 172
2023
Q2 		$703K Buy
+56
New +$703K 0.07% 235

Other funds holding ASBP

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fir Tree Capital Management's ASBP Position: Q2 2024 in Review

Fir Tree Capital Management sold out of Aspire Biopharma (ASBP) in Q2 2024, closing a stake of 177 shares — an estimated $2.35M sold.

Fir Tree Capital Management first reported a position in ASBP in Q2 2023 and held it in 4 quarters. The position peaked at $2.35M in Q1 2024. 3 funds tracked by Wall St. Rank hold ASBP as of Q2 2024.

  • Fir Tree Capital Management reported no remaining Aspire Biopharma position as of Q2 2024 after selling out during the quarter.
  • Fir Tree Capital Management sold 177 Aspire Biopharma shares in Q2 2024, an estimated $2.35M.
  • Fir Tree Capital Management first reported a position in Aspire Biopharma in Q2 2023 and held it in 4 quarters.
  • Fir Tree Capital Management's Aspire Biopharma position peaked at $2.35M in Q1 2024.
  • 3 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2024.

Based on Fir Tree Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.